Diabetes and Cell Biology of Diabetes Laboratory, BakerIDI Heart and Diabetes Institute, Commercial Road, Melbourne, Victoria 3141, Australia.
Eur J Pharmacol. 2010 Jan 25;626(2-3):186-92. doi: 10.1016/j.ejphar.2009.09.066. Epub 2009 Oct 8.
Platelet-derived growth factor (PDGF) receptor signalling is implicated in cardiovascular diseases such as atherosclerosis and restenosis. PDGF expression levels are elevated in atherosclerotic lesions and play a key role in migration and proliferation of vascular smooth muscle cells in the neointima. PDGF stimulates glycosaminoglycan elongation on vascular proteoglycans biglycan and decorin, a process implicated in the aetiology of atherosclerosis. We investigated the ability of the specific kinase inhibitor Ki11502 to inhibit PDGF beta receptor phosphorylation and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 inhibited PDGF-mediated tyrosine phosphorylation of the PDGF beta receptor autophosphorylation site and at least six other receptor-associated proteins. Ki11502 also caused a concentration-dependent inhibition of PDGF-stimulated [(3)H]-thymidine incorporation. Total proteoglycan synthesis was assessed as incorporation of [(35)S]-sulfate. PDGF-induced a two-fold increase in [(35)S]-sulfate incorporation into proteoglycans secreted over 24h and was inhibited in a concentration-dependent manner by Ki11502. PDGF treatment resulted in a statistically significant (P<0.01) increase in total proteoglycan core protein secretion. Treatment of cells with Ki11502 (300 nM) had no effect on basal core protein secretion and completely abolished the PDGF-stimulated component. Analysis of isolated cleaved glycosaminoglycan chains by size-exclusion chromatography demonstrated that PDGF stimulated the synthesis and secretion of proteoglycans with elongated glycosaminoglycan chains and this effect was inhibited by Ki11502. Inhibition was also seen in the length of xyloside-glycosaminoglycan chains. The results demonstrate that Ki11502 is a potent and selective inhibitor of PDGF beta receptor phosphorylation, proliferation and proteoglycan synthesis in human vascular smooth muscle cells.
血小板衍生生长因子(PDGF)受体信号转导与动脉粥样硬化和再狭窄等心血管疾病有关。在动脉粥样硬化病变中,PDGF 的表达水平升高,在新内膜中血管平滑肌细胞的迁移和增殖中起关键作用。PDGF 刺激血管蛋白聚糖 biglycan 和 decorin 上糖胺聚糖的延伸,这一过程与动脉粥样硬化的发病机制有关。我们研究了特异性激酶抑制剂 Ki11502 抑制人血管平滑肌细胞中 PDGFβ受体磷酸化和蛋白聚糖合成的能力。Ki11502 抑制 PDGF 介导的 PDGFβ受体自身磷酸化位点和至少其他六个受体相关蛋白的酪氨酸磷酸化。Ki11502 还导致 PDGF 刺激的 [(3)H]-胸苷掺入呈浓度依赖性抑制。总蛋白聚糖合成的评估为 [(35)S]-硫酸盐的掺入。PDGF 诱导 [(35)S]-硫酸盐掺入 24 小时内分泌的蛋白聚糖增加两倍,并被 Ki11502 浓度依赖性抑制。PDGF 处理导致总蛋白聚糖核心蛋白分泌的统计学显著增加(P<0.01)。用 Ki11502(300 nM)处理细胞对基础核心蛋白分泌没有影响,并完全消除了 PDGF 刺激的成分。通过大小排阻色谱法对分离的裂解糖胺聚糖链进行分析表明,PDGF 刺激具有延伸糖胺聚糖链的蛋白聚糖的合成和分泌,这种作用被 Ki11502 抑制。木糖苷-糖胺聚糖链的长度也观察到抑制。结果表明,Ki11502 是一种有效的 PDGFβ受体磷酸化、增殖和人血管平滑肌细胞蛋白聚糖合成的选择性抑制剂。